CoChat

Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy

Open access

The DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index; 128 of the 188 sources its claims cite were checked for support.

Abstract

The advent of induced pluripotent stem cells (iPSCs) has advanced our understanding of the molecular mechanisms of human disease, drug discovery, and regenerative medicine. As such, the use of iPSCs in drug development and validation has shown a sharp increase in the past 15 years. Furthermore, many labs have been successful in reproducing many disease phenotypes, often difficult or impossible to capture, in commonly used cell lines or animal models. However, there still remain limitations such as the variability between iPSC lines as well as their maturity. Here, we aim to discuss the strategies in generating iPSC-derived cardiomyocytes and neurons for use in disease modeling, drug development and their use in cell therapy.

Overview

CoChat Summary

TL;DR

This review discusses how induced pluripotent stem cell (iPSC)-derived cardiomyocytes, neurons, and organoids are used for disease modeling, drug discovery, and cell therapy, with emphasis on cardiovascular and neurological applications. It also covers remaining hurdles including iPSC line variability, cell immaturity, and immune rejection in transplantation.

Key findings

  • iPSC-derived cardiomyocytes recapitulate cardiac channelopathies and cardiomyopathies and have enabled drug discovery: e.g., nicorandil and PD118057 shortened action potentials in type-2 LQTS cells, mexiletine analogues enhanced INa potency/selectivity for type-3 LQTS, and verapamil showed the strongest inhibition of contractile function among four calcium channel blockers tested in HCM cells.
  • iPSC-derived neurons model AD, PD, ALS, ASD, and SMA; examples include docosahexaenoic acid alleviating stress responses in AD neurons, Coenzyme Q10/rapamycin/GW5074 in LRRK2- and PINK1-mutant PD cells, ropinirole in TDP-43/FUS ALS motor neurons, and IGF-1 or hyperforin rescuing TRPC6-mutant ASD neuronal abnormalities.
  • Organoid platforms support screening: >10,000 cardiac organoids were screened to identify optimal maturation conditions; >1000 FDA-approved drugs were screened in hPSC-forebrain organoids, identifying hippeastrine hydrobromide against ZIKV; a 50,000-compound screen in fragile X neuronal progenitors identified compounds inducing FMRP expression.
  • HLA-homozygous iPSC banking can cover large populations from few donors: 55 donors for ~80% of the Japanese population, 150 iPSC lines for ~93% of the UK, 140 lines for ~90% of Japan, and ~80 lines for 50% coverage in California; CiRA's three clinical-grade lines cover 32% of Japan, Korea's 10 lines cover 41%, and Taiwan's 13 lines cover ~16% of Taiwanese.

Methods

  • Narrative review (no primary data collection) covering iPSC generation and differentiation into cardiomyocytes, neurons, and organoids for disease modeling, drug discovery, and cell therapy.
  • Synthesizes published preclinical and clinical studies, including high-throughput screening studies, HLA banking calculations, and CRISPR/Cas9 genome-editing approaches.
  • Includes a table (Table 1) outlining iPSC-based clinical trials current as of 2021.

Limitations

  • Stated by the paper: iPSC-derived cells are immature and lack intercellular communication, making complex adult disease mimicry difficult; many diseases are polygenic/heterogeneous (e.g., ASD) so a single patient line may not yield a single hit compound; reprogramming and differentiation protocol reproducibility is a recurring issue; 5–46% of phenotypic variability in iPSCs stems from normal human genetic variation (inter- and intraclone); high-throughput miniaturization challenges include low cell numbers, media evaporation, and low-volume dispensing accuracy; organoids represent fetal-like rather than adult structures; CRISPR/Cas9 off-target cleavage risks oncogenic mutations; HLA-edited cells carry increased tumorigenicity risk; autologous transplantation is time-consuming and expensive.
  • Evident from the text: the review is descriptive and does not present new experimental data; several cited clinical trials (e.g., Help Therapeutics Phase 1/2, Cuorips/Osaka Phase 1) lacked efficacy data at the time of writing.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cells11111853

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Disease modeling and drug screening using patient-specific induced pluripotent stem cells.
Figure 1 Disease modeling and drug screening using patient-specific induced pluripotent stem cells.CC BY · PubMed Central

Verification

Claims the paper makes

87 Valid · 19 Not valid · 34 Not checked · 39 Own results and interpretations

100 more claims · 53 with their cited sources checked

Create a free account to see all 179 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 54
  • Probably not a substantial claim. 27

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Cited by

See all 65

Metadata

Authors
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H.
Affiliations
Institute of Biomedical Sciences, Academia Sinica (TW)
Corresponding author
Hsieh, Patrick C. H.
Venue
Cells
Publisher
MDPI AG
Published
2022-06-06
Volume
11
Issue
11
Pages
1853
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4281701292
Cited by
65
References
132
Citations by year
2026: 10 · 2025: 21 · 2024: 15 · 2023: 17 · 2022: 2
FWCI
1.39
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords
induced pluripotent stem cells, iPSC-derived cardiomyocytes, iPSC-derived neurons, disease modeling, drug development, cell therapy, regenerative medicine
MeSH terms
Drug Development, Animals, Pluripotent Stem Cells, Regenerative Medicine, Induced Pluripotent Stem Cells, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.